8/15/2014

Allergan will pay $67.5 million in cash and as much as $520 in milestone fees to acquire global rights to TARIS Biomedical's lead candidate LiRIS, which is under development for interstitial cystitis/bladder pain syndrome treatment. The deal will boost Allergan's urology pipeline, the firm said.

Related Summaries